TD Cowen analyst Phil Nadaeu reiterated a Buy rating on Enliven Therapeutics (NASDAQ: ELVN).The analyst commented, "ELVN ended Q2 with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE